Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: Current evidence and new perspectives

被引：5

作者：

de Scordilli, Marco ^{[1
,2
]}

Michelotti, Anna ^{[1
,3
]}

Zara, Diego ^{[1
,2
]}

Palmero, Lorenza ^{[1
,2
]}

Alberti, Martina ^{[1
,3
]}

Noto, Claudia ^{[1
,2
]}

Totaro, Fabiana ^{[1
,2
]}

Foltran, Luisa ^{[2
]}

Guardascione, Michela ^{[2
]}

Iacono, Donatella ^{[3
]}

Ongaro, Elena ^{[2
]}

Fasola, Gianpiero ^{[3
]}

Puglisi, Fabio ^{[1
,2
]}

机构：

[1] Univ Udine, Dept Med DAME, I-33100 Udine, Italy

[2] IRCCS, Ctr Riferimento Oncol Aviano CRO, Dept Med Oncol, I-33081 Aviano, Italy

[3] ASUFC Univ Hosp Udine, Dept Oncol, I-33100 Udine, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2023年 / 186卷

关键词：

Pancreatic adenocarcinoma; Locally advanced pancreatic cancer; Borderline resectable pancreatic cancer; Resectable pancreatic cancer; Neoadjuvant therapy; Preoperative treatment; PHASE-III TRIAL; GEMCITABINE PLUS PLACEBO; SECRETING TUMOR VACCINE; DUCTAL ADENOCARCINOMA; NAB-PACLITAXEL; POSTOPERATIVE COMPLICATIONS; NEOADJUVANT CHEMOTHERAPY; RANDOMIZED-TRIAL; MANAGEMENT; THERAPY;

D O I：

10.1016/j.critrevonc.2023.104013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Surgery is the only curative treatment for non-metastatic pancreatic adenocarcinoma, but less than 20 % of patients present a resectable disease at diagnosis. Treatment strategies and disease definition for borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC) vary in the different cancer centres. Preoperative chemotherapy (CT) is the standard of care for both BRPC and LAPC patients, however literature data are still controversial concerning the type, dose and duration of the different CT regimens, as well as regarding the integration of radiotherapy (RT) or chemoradiation (CRT) in the therapeutic algorithm. In this unsettled debate, we aimed at focusing on the therapeutic regimens currently in use and relative literature data, to report international trials comparing the available therapeutic options or explore the introduction of new pharmacological agents, and to analyse possible new scenarios in microenvironment evaluation before and after neoadjuvant therapies or in patients' selection at a molecular level.

引用

页数：11

共 106 条

[71] Circulating Tumor Cells Enumeration from the Portal Vein for Risk Stratification in Early Pancreatic Cancer Patients [J].

Padillo-Ruiz, Javier ;

Suarez, Gonzalo ;

Pereira, Sheila ;

Calero-Castro, Francisco Jose ;

Tinoco, Jose ;

Marin, Luis ;

Bernal, Carmen ;

Cepeda-Franco, Carmen ;

Alamo, Jose Maria ;

Almoguera, Francisco ;

Macher, Hada C. ;

Villanueva, Paula ;

Garcia-Fernandez, Francisco Jose ;

Gallego, Inmaculada ;

Romero, Manuel ;

Gomez-Bravo, Miguel Angel ;

Denninghoff, Valeria ;

Serrano, Maria Jose .

CANCERS, 2021, 13 (24)

[72] Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study [J].

Philip, Philip A. ;

Lacy, Jill ;

Portales, Fabienne ;

Sobrero, Alberto ;

Pazo-Cid, Roberto ;

Manzano Mozo, Jose L. ;

Kim, Edward J. ;

Dowden, Scot ;

Zakari, Ahmed ;

Borg, Christophe ;

Terrebonne, Eric ;

Rivera, Fernando ;

Sastre, Javier ;

Bathini, Venu ;

Lopez-Trabada, Daniel ;

Asselah, Jamil ;

Saif, Muhammad Wasif ;

Li, Jack Shiansong ;

Ong, Teng Jin ;

Nydam, Thomas ;

Hammel, Pascal .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (03) :285-294

[73] Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205 [J].

Philip, Philip A. ;

Benedetti, Jacqueline ;

Corless, Christopher L. ;

Wong, Ralph ;

O'Reilly, Eileen M. ;

Flynn, Patrick J. ;

Rowland, Kendrith M. ;

Atkins, James N. ;

Mirtsching, Barry C. ;

Rivkin, Saul E. ;

Khorana, Alok A. ;

Goldman, Bryan ;

Fenoglio-Preiser, Cecilia M. ;

Abbruzzese, James L. ;

Blanke, Charles D. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (22) :3605-3610

[74] Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer [J].

Picozzi, Vincent ;

Alseidi, Adnan ;

Winter, Jordan ;

Pishvaian, Michael ;

Mody, Kabir ;

Glaspy, John ;

Larson, Timothy ;

Matrana, Marc ;

Carney, Mairead ;

Porter, Seth ;

Kouchakji, Elias ;

Rocha, Flavio ;

Carrier, Ewa .

ESMO OPEN, 2020, 5 (04)

[75] A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma [J].

Reni, Michele ;

Zanon, Silvia ;

Balzano, Gianpaolo ;

Passoni, Paolo ;

Pircher, Chiara ;

Chiaravalli, Marta ;

Fugazza, Clara ;

Ceraulo, Domenica ;

Nicoletti, Roberto ;

Arcidiacono, Paolo Giorgio ;

Macchini, Marina ;

Peretti, Umberto ;

Castoldi, Renato ;

Doglioni, Claudio ;

Falconi, Massimo ;

Partelli, Stefano ;

Gianni, Luca .

EUROPEAN JOURNAL OF CANCER, 2018, 102 :95-102

[76]

Reni M, 2018, LANCET GASTROENTEROL, V3, P413, DOI [10.1016/S2468-1253(18)30081-5, 10.1016/S2468-1253(18)30196-1]

[77] Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma [J].

Royal, Richard E. ;

Levy, Catherine ;

Turner, Keli ;

Mathur, Aarti ;

Hughes, Marybeth ;

Kammula, Udai S. ;

Sherry, Richard M. ;

Topalian, Suzanne L. ;

Yang, James C. ;

Lowy, Israel ;

Rosenberg, Steven A. .

JOURNAL OF IMMUNOTHERAPY, 2010, 33 (08) :828-833

[78] Tumor penetrating peptides for improved drug delivery [J].

Ruoslahti, Erkki .

ADVANCED DRUG DELIVERY REVIEWS, 2017, 110 :3-12

[79] Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer [J].

Seppala, Toni T. ;

Zimmerman, Jacquelyn W. ;

Sereni, Elisabetta ;

Plenker, Dennis ;

Suri, Reecha ;

Rozich, Noah ;

Blair, Alex ;

Thomas, Dwayne L., II ;

Teinor, Jonathan ;

Javed, Ammar ;

Patel, Hardik ;

Cameron, John L. ;

Burns, William R. ;

He, Jin ;

Tuveson, David A. ;

Jaffee, Elizabeth M. ;

Eshleman, James ;

Szabolcs, Annamaria ;

Ryan, David P. ;

Ting, David T. ;

Wolfgang, Christopher L. ;

Burkhart, Richard A. .

ANNALS OF SURGERY, 2020, 272 (03) :427-435

[80] Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)da randomized phase II trial of the AIO pancreatic cancer group [J].

Seufferlein, T. ;

Uhl, W. ;

Kornmann, M. ;

Alguel, H. ;

Friess, H. ;

Koenig, A. ;

Ghadimi, M. ;

Gallmeier, E. ;

Bartsch, D. K. ;

Lutz, M. P. ;

Metzger, R. ;

Wille, K. ;

Gerdes, B. ;

Schimanski, C. C. ;

Graupe, F. ;

Kunzmann, V. ;

Klein, I. ;

Geissler, M. ;

Staib, L. ;

Waldschmidt, D. ;

Bruns, C. ;

Wittel, U. ;

Fichtner-Feigl, S. ;

Daum, S. ;

Hinke, A. ;

Blome, L. ;

Tannapfel, A. ;

Kleger, A. ;

Berger, A. W. ;

Kestler, A. M. R. ;

Schuhbaur, J. S. ;

Perkhofer, L. ;

Tempero, M. ;

Reinacher-Schick, A. C. ;

Ettrich, T. J. .

ANNALS OF ONCOLOGY, 2023, 34 (01) :91-100

← 2 3 4 5 6 7 8 9 10 11 →